- Home
- VCEL vs ACGLO Comparison
VCEL vs ACGLO Comparison
Compare VCEL & ACGLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCEL
- ACGLO
- Stock Information
- Founded
- VCEL 1989
- ACGLO N/A
- Country
- VCEL United States
- ACGLO Bermuda
- Employees
- VCEL N/A
- ACGLO 5800
- Industry
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- ACGLO Property-Casualty Insurers
- Sector
- VCEL Health Care
- ACGLO Finance
- Exchange
- VCEL Nasdaq
- ACGLO Nasdaq
- Market Cap
- VCEL 2.1B
- ACGLO N/A
- IPO Year
- VCEL 1997
- ACGLO N/A
- Fundamental
- Price
- VCEL $40.25
- ACGLO $20.65
- Analyst Decision
- VCEL Strong Buy
- ACGLO
- Analyst Count
- VCEL 8
- ACGLO 0
- Target Price
- VCEL $62.00
- ACGLO N/A
- AVG Volume (30 Days)
- VCEL 477.0K
- ACGLO N/A
- Earning Date
- VCEL 07-31-2025
- ACGLO N/A
- Dividend Yield
- VCEL N/A
- ACGLO N/A
- EPS Growth
- VCEL 521.85
- ACGLO N/A
- EPS
- VCEL 0.05
- ACGLO N/A
- Revenue
- VCEL $238,541,000.00
- ACGLO N/A
- Revenue This Year
- VCEL $23.03
- ACGLO N/A
- Revenue Next Year
- VCEL $24.52
- ACGLO N/A
- P/E Ratio
- VCEL $780.58
- ACGLO N/A
- Revenue Growth
- VCEL 14.80
- ACGLO N/A
- 52 Week Low
- VCEL $37.39
- ACGLO N/A
- 52 Week High
- VCEL $63.00
- ACGLO N/A
- Technical
- Relative Strength Index (RSI)
- VCEL 44.06
- ACGLO 58.44
- Support Level
- VCEL $39.39
- ACGLO $20.50
- Resistance Level
- VCEL $42.61
- ACGLO $20.77
- Average True Range (ATR)
- VCEL 1.73
- ACGLO 0.20
- MACD
- VCEL -0.15
- ACGLO 0.03
- Stochastic Oscillator
- VCEL 24.16
- ACGLO 89.19
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
About ACGLO Arch Capital Group Ltd. Depositary Shares Each Representing 1/1000th Interest in a Share of 5.45% Non-Cumulative Preferred Shares Series F
Arch Capital Group Ltd is a Bermuda company that writes insurance and reinsurance with operations in the United States, Canada, Europe, Australia, and the United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage. The insurance segment provides specialty risk solutions to clients across various industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.